Such designs could determine whether immunometabolic improvements translate into slower progression from subclinical to overt hypothyroidism or reduced relapse in Graves disease
This means they can potentially cause a blood sugar spike, followed by an energy crash and increased hunger
Thyroid cancer : Possible risk of thyroid tumors based on rodent studies
The extended half-life of approximately 7 days is due to albumin binding and resistance to DPP-4 degradation, enabling convenient once-weekly dosing [1]
Keywords: autoimmune thyroid disease, glp-1 receptor agonists, graves disease, hashimoto thyroiditis, immunometabolism, obesity, semaglutide, thyroid autoimmunity, tirzepatide Introduction and background Introduction Autoimmune thyroid disease (AITD), encompassing Hashimoto thyroiditis and Graves disease, is the most common organ-specific autoimmune disorder, affecting up to 5% of the general population, with a marked female predominance of nearly 5:1 compared with men [1,2]
Parallel to this, Semaglutide also has immunogenic properties of high potential to produce anti-Semaglutide antibodies
